Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Colorectal Adenocarcinoma|Ewing Sarcoma
DRUG: INBRX-109|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Pemetrexed|DRUG: 5-fluorouracil|DRUG: Irinotecan|DRUG: Temozolomide
Frequency and severity of adverse events of INBRX-109, Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0., Up to 8 years|Evaluating Tumor Response for colorectal cancers and Ewing sarcoma, Evaluating how the tumor responds to treatment by measuring the number of patients with colorectal cancer and Ewing sarcoma that experience tumor shrinkage and for how long., Up to 8 years
Immunogenicity of INBRX-109, Frequency of ant-drug antibodies (ADA) against INBRX-109 will be determined., Up to 8 years|Characterize the pharmacokinetics of INBRX-109 as a single agent, and of INBRX-109 in combination with distinct chemotherapies., A measurement which indicates how the body processes INBRX-109 and how long it stays in the system., Up to 8 years|Median progression-free survival for colorectal adenocarcinoma and Ewing sarcoma., Progression-free survival is defined as the time from start of study treatment until documented disease progression or death., Up to 8 years
Anti-tumor activity of INBRX-109, Tumor response will be determined by RECISTv1.1., Up to 8 years|Potential predictive response biomarkers, Evaluate the relationship between potential predictive response biomarkers and efficacy of INBRX-109, Up to 8 years
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).